Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 juil. 2024 16h30 HE
|
Vera Therapeutics
BRISBANE, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 1, 2024, the Compensation Committee of Vera’s Board of Directors granted...
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
01 juil. 2024 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
11 juin 2024 16h01 HE
|
Vera Therapeutics
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 juin 2024 16h05 HE
|
Vera Therapeutics
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 4, 2024, the Compensation Committee of Vera’s Board of Directors granted...
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
07 juin 2024 16h05 HE
|
Vera Therapeutics
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
28 mai 2024 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
25 mai 2024 09h40 HE
|
Vera Therapeutics
72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract;Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater...
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
09 mai 2024 08h00 HE
|
Vera Therapeutics
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 mai 2024 16h38 HE
|
Vera Therapeutics
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted...
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
02 avr. 2024 08h00 HE
|
Vera Therapeutics
72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02,...